Douglas Langemeier, PA
Medical · Nebraska City, NENPI 1528076171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations.
Across 97 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$338
- Lilly USA, LLC$200
- Novo Nordisk$167
- Novartis$149
- Amgen$128
- Pfizer$112
- plus $481 from 16 others
What the payments were for
- Food & beverage$1,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $338 |
| Lilly USA, LLC | 13 | $200 |
| Novo Nordisk | 11 | $167 |
| Novartis | 10 | $149 |
| Amgen | 10 | $128 |
| Pfizer | 6 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $62 |
| AstraZeneca | 4 | $55 |
| Amarin Pharma, Inc. | 2 | $39 |
| Bayer | 3 | $38 |
| Boehringer Ingelheim | 2 | $30 |
| Grifols USA, LLC | 2 | $30 |
| Astellas Pharma US Inc | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Merck | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Galderma Laboratories, L.p. | 1 | $11 |
How this compares
$1,575 in reported general payments places this provider in the 75th percentile of 216 medical providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 11 | $411 |
| Prednisone | 19 | $51 |
| Tramadol Hcl | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Other medical in Nebraska City
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Kelly HooverOmaha$16K
- Lyndsey DegenhardtElkhorn$12K
- Jacob RidderOmaha$12K
- Angelika StevensOmaha$8K
- Jennelea MontanezOmaha$8K
- Shannon BusterPapillion$8K
- Jay ArthurLincoln$8K
- Carmen MagistroBellevue$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.